Biodexa Pharmaceuticals Plc

NasdaqCM:BDRX Stok Raporu

Piyasa değeri: US$3.4m

Biodexa Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Biodexa Pharmaceuticals has been growing earnings at an average annual rate of 19.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 21.6% per year.

Anahtar bilgiler

19.2%

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı-21.6%
Özkaynak getirisi-78.1%
Net Marj-8,215.7%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Midatech Pharma regains compliance with Nasdaq's minimum bid price requirement

Oct 18

Midatech Pharma reports 1H results

Sep 14

Midatech surges on the promise of drug delivery system

Jun 17

Gelir ve Gider Dağılımı

Biodexa Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:BDRX Gelir, gider ve kazançlar (GBP Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 240-734
31 Mar 240-734
31 Dec 230-734
30 Sep 230-832
30 Jun 231-840
31 Mar 231-830
31 Dec 221-830
30 Sep 221-730
30 Jun 221-530
31 Mar 221-530
31 Dec 211-530
30 Sep 211-740
30 Jun 211-830
31 Mar 210-1540
31 Dec 200-2250
30 Jun 200-2250
31 Mar 201-1650
31 Dec 191-940
30 Jun 192-940
31 Mar 192-1040
31 Dec 182-1040
30 Jun 181-1140
31 Mar 181-1140
31 Dec 171-1240
30 Sep 17-3-1-7-5
30 Jun 174-18106
31 Mar 176-19147
31 Dec 161-630
30 Sep 165-171210
30 Jun 164-13136
31 Mar 163-1296
31 Dec 151-1039
30 Sep 151-1065
30 Jun 150-1174
31 Mar 150-1064
31 Dec 140-944
30 Sep 140-743
30 Jun 140-523
31 Mar 140-423
31 Dec 130-423

Kaliteli Kazançlar: BDRX is currently unprofitable.

Büyüyen Kar Marjı: BDRX is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BDRX is unprofitable, but has reduced losses over the past 5 years at a rate of 19.2% per year.

Büyüme Hızlandırma: Unable to compare BDRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: BDRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: BDRX has a negative Return on Equity (-78.14%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin